ArticleCommunications biology2022
Commercialized artemisinin derivatives combined with colistin protect against critical Gram-negative bacterial infection.
Article in Communications biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 29 citations in OpenAlex.
- Development and evaluation of a multi-epitope subunit vaccine against Salmonella Enteritidis infection.Poultry science · 2026Article
- Identification and protective efficacy characterization of novel immunogenic antigens for Salmonella Enteritidis vaccines.Poultry science · 2026Article
- Article
- Copper ions restore antibacterial activity of tigecycline by regulating photodegradation pathway under light exposure.Communications biology · 2026Article
- Antibacterial mechanism and in vivo efficacy of cladribine against carbapenem-resistant Klebsiella pneumoniae.BMC microbiology · 2026Article
- Mechanistic insights into phthalylsulfacetamide-induced restoration of meropenem bactericidal activity in NDM-1-positive Escherichia coli.BMC microbiology · 2026Article
- Innovative application of mefloquine and Methacycline in combating Tet(X3/X4)-positive Escherichia coli infections.BMC microbiology · 2025Article
- β,β-Dimethylacrylalkannin Restores Colistin Efficacy AgainstAntibiotics (Basel, Switzerland) · 2025Article
- Dronedarone hydrochloride targets cardiolipin and phosphatidylglycerol to increase colistin susceptibility in gram-negative pathogens.Microbiology spectrum · 2025Article
- The fatty acid synthesis geneMicrobiology spectrum · 2025Article
- The Enzyme Glucose-1-Phosphate Thymidylyltransferase RmlA Plays a Crucial Role in the Pathogenesis of Pectobacterium actinidiae GX1.Molecular plant pathology · 2025Article
- Artesunate, EDTA, and colistin work synergistically against MCR-negative and -positive colistin-resistanteLife · 2025Article
- Nicorandil reduces the antimicrobial effectiveness of polymyxin E againstFrontiers in cellular and infection microbiology · 2025Article
- Molecular mechanism of crisaborole combined with erythromycin against methicillin-resistantFrontiers in microbiology · 2025Article
- Restoring Colistin Sensitivity in Multidrug-Resistant PathogenicInternational journal of molecular sciences · 2024Article
- Restoring colistin sensitivity in colistin-resistantmSphere · 2024Article
- Article
- The Combination of Antibiotic and Non-Antibiotic Compounds Improves Antibiotic Efficacy against Multidrug-Resistant Bacteria.International journal of molecular sciences · 2023Review
- Structural-Activity Relationship-Inspired the Discovery of Saturated Fatty Acids as Novel Colistin Enhancers.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Dihydroartemisinin inhibits plasmid transfer in drug-resistantZoological research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence and spread of the mcr-1 gene and its mutants has immensely compromised the efficient usage of colistin for the treatment of drug-resistant Gram-negative bacterial infection in clinical settings. However, there are currently no clinically available colistin synergis. Here we identify artemisinin derivatives, such as dihydroartemisinin (DHA), that produces a synergistic antibacterial effect with colistin against the majority of Gram-negative bacteria (FIC < 0.5) without induced resistance, particularly those carrying the mcr-1 gene. Mechanism analysis reveals the direct engagement of DHA with the active center of MCR-1 to inhibit the activity of MCR-1. Meanwhile, the results from transcriptome and electron microscope analysis show that DHA could also simultaneously affect the flagellar assembly and the energy metabolism of bacteria. Moreover, in the mouse infection models of Gram-negative bacteria, combination therapy shows remarkable treatment benefits, as shown by an improved survival rate, reduced morbidity, alleviated pathological injury and decreased bacterial loading. Due to the generally safe profile of specialized malaria medication administration in humans, artemisinin derivatives are a promising class of multi-target inhibitors on bacterial resistance and virulence that can be used to extend the usage life of colistin and to tackle the inevitability of serious bacterial infection with colistin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.